Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)

09/03/2021 | 05:18pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 2, 2021, the compensation committee (the "Compensation Committee") of the Board of Directors of VYNE Therapeutics Inc. (the "Company") approved the grant of an aggregate of 1,204,909 shares subject to restricted stock unit and stock option awards to all continuing employees of the Company, including members of management. The awards will be issued in accordance with the terms and conditions of the Company's 2019 Equity Incentive Plan and the 2018 Omnibus Incentive Plan and the underlying award agreements. The Compensation Committee determined such grants are appropriate to address the need to adequately retain the Company's employees through this period of strategic change and incentivize employees to effectively execute the Company's new strategic operating plan, as disclosed on August 12, 2021, and closely align the interests of employees with the Company's stockholders over the long term.

David Domzalski, the Company's Chief Executive Officer, was awarded 320,312 restricted stock unit awards and employee stock options to purchase 320,313 shares. Iain Stuart, the Company's Chief Scientific Officer, Tyler Zeronda, the Company's Chief Financial Officer, and Mutya Harsch, the Company's Chief Legal Officer, were each awarded 60,859 restricted stock unit awards and employee stock options to purchase 60,860 shares. All of the shares subject to restricted stock unit awards will vest on September 30, 2023, and 50% of the shares subject to stock option awards will vest on September 30, 2022, with the remaining 50% of the shares vesting thereafter in equal, quarterly installments, in each case, subject to the recipient's continued service to the Company through the vesting date. The exercise price for each stock option granted is $1.68 per share, which represents the closing price for the Company's common stock on the date of grant.

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
10/21VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S..
MT
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
10/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
10/19VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o..
CI
10/05VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
10/05VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 ..
CI
09/20VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
09/08VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,88x
Yield 2021 -
Capitalization 60,8 M 60,8 M -
Capi. / Sales 2021 3,33x
Capi. / Sales 2022 8,47x
Nbr of Employees 106
Free-Float 87,2%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,18 $
Average target price 6,67 $
Spread / Average Target 465%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-81.33%61
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158